Activity Summary:
In the past decade, it has become increasingly clear that women and men with stable ischemic heart disease often present with different signs and symptoms. Some of these differences can reflect gender-based differences in disease pathophysiology and risks for clinical cardiovascular events, as well as the need for different diagnostic methods and treatment strategies.

These educational Mini Modules will outline the epidemiologic trends as well as the health and economic burden of SIHD in women. In addition, discussion will include gender-specific pathophysiologic factors in SIHD, diagnostic approaches, risk stratification, and management approaches in women with stable ischemic heart disease.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
As therapy and our understanding of the HIV disease process progresses, so do our management approaches, as noted by the multiple updates issued by the DHHS and IAS-USA on their guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Guideline updates such as these have a rapid impact on application to clinical practice, affecting treatment strategies and preferences in HIV patient management. New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of HIV treatment as HIV prevention and development of long-acting novel agents.

This Conversations in HIV will discuss evolving treatment options in HIV, such as the benefits and risks of 2 vs 3 drug therapy, integrase inhibitor vs protease inhibitor use and what’s on the horizon in antiretroviral therapy.

Activity Summary:
Advances in hepatitis C research unfold rapidly. Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care.

These educational Mini Modules from the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2017 will explain how recent study results in HCV apply to clinical practice and discuss significant developments and strategies in HCV therapy and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of HIV and related comorbidities through a series of daily, ‘what you need to know in 5 minutes’ videos each day from the 2017 European AIDS Clinical Society (EACS) Conference in Milan, Italy.

Activity Summary:
Clinical management of the newly diagnosed patient with PAH requires a strong multidisciplinary team.

These educational Mini Modules will outline the most-recent guidelines for initiating PAH therapy in the newly diagnosed as well as team roles in managing patients through the process of dealing with this life-threatening condition.

Updated information is noted on the slide in the upper right-hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Reducing the risk of death and major cardiovascular events are major goals of therapy for people with stable ischemic heart disease. Many management decisions hinge on a patient’s risk for these events, and recent and ongoing trials are helping to clarify treatment decisions in patients in different risk categories.

These educational Mini Modules will outline the role of medical therapies and revascularization when the goal of therapy is to reduce cardiovascular events and improve survival.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Recognizing and discussing significant developments and strategies in HCV therapy places healthcare professionals at the forefront of hepatitis care. This activity will explain how recent study results in HCV apply to clinical practice, discuss significant developments and strategies in HCV therapy, discuss results from key clinical studies on new antiviral therapy, and describe recent data on drug toxicity/adverse events, drug interactions, and strategies for HCV management.

These educational Clinical Clips will spotlight the latest advances in the prevention and treatment of hepatitis C through a series of daily, ‘what you need to know in 5-minutes’ videos each day from AASLD 2017.

Activity Summary:
Chronic infection with hepatitis C virus (HCV) is a serious health issue for the nearly 200 million infected persons worldwide. Achievement of a SVR may be associated with improved long-term clinical outcomes, including increased survival. Because of the intricacies and challenges associated with monitoring disease status and HCV treatment, healthcare providers often turn to guideline recommendations and best practices when tailoring therapy to achieve the best results for the individual patient.

These Mini Modules will review the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) recommendations on the use of HCV regimens for HCV genotypes 1 through 6, including treatment eligibility and when to start therapy.

Activity Summary:
A number of organizations have recommended the use of PrEP to people at greatest risk of HIV acquisition. However there remains a significant gap between proving efficacy in clinical trials and achieving effectiveness in the real-world setting. Although clinical trial data provide an initial framework for the efficacy and safety of PrEP, a number of questions and concerns remain about how to use PrEP in everyday clinical practice as well as its impact on reducing HIV incidence.

These educational mini modules discuss the lessons learned from PrEP demonstration projects and open-label extension studies on approaches to mitigate potential barriers to PrEP uptake and strategies to improve integration of PrEP into existing clinical practices.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease.

No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options. These educational Mini Modules will review the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Mini Modules cover data from IAS 2017 including epidemiologic trends, prevention strategies, recommendations for therapy, future ARV therapy, and HIV comorbidity management.

Activity Summary:
While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).

Activity Summary:
Major goals of therapy for people with stable ischemic heart disease (SIHD) include reducing angina symptoms and improving functional ability and quality of life. Recent developments in the use of medical therapies and re-evaluations of older therapies have brought some important changes to the treatment of these patients. Application of the results of revascularization trials and current recommendations requires careful and skillful risk stratification as well as a thorough understanding of the trial designs and results.

These educational Mini Modules will outline how recent developments and clinical trials influence the management of symptoms and functional limitations in real-world patients with stable ischemic heart disease.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.

Activity Summary:
Diabetes is a strong risk factor for cardiovascular disease, and it influences management and outcomes of existing disease.

These educational Mini Modules will outline how diabetes influences the onset and management of stable ischemic heart disease (SIHD), including choices of medical therapies and decisions about the use of revascularization strategies.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Management of patients with PAH requires a holistic, multidisciplinary effort. Nurses working in the fields of pulmonology, cardiology, rheumatology, and intensive care should have a clear understanding of the diagnostic criteria, quality-of-life issues and medical management considerations for patients diagnosed with pulmonary arterial hypertension.

These educational Mini Modules will outline appropriate diagnostic testing, the risk-benefit equation for specific PAH therapies and associated treatments, and nursing methods of support in crucial clinical management roles to improve patient quality-of-life and medical outcomes.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Chronic hepatitis B virus (HBV) infection is a prevalent medical condition in the United States and leads to significant morbidity and mortality.

These educational Mini Modules review the burden of chronic HBV infection, describes the various serum markers of HBV infection and their clinical importance, and reviews evidence-based and AASLD treatment recommendations for chronic HBV infection. Furthermore, the results from recent clinical trials of preferred HBV antiviral agents are discussed.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Because the field of ART continues to evolve rapidly and best practice changes over time, there is a need for those treating HIV infections to consider expert opinion and guidelines in the context of the needs and beliefs of individual patients to tailor therapy and achieve best results.

These educational mini modules include new advances in care, what antiretrovirals to select for different types of patients, prevention, and emerging trends impacting the clinical management of HIV patients.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Individualizing HIV for simplified and convenient regimens challenges caregivers to systematically evaluate a number of factors, including pill burden, potential toxicities, lifestyle changes, and psychosocial circumstances. The need for simplified ART is recognized by recent treatment guidelines published by the Department of Health and Human Services and the International AIDS Society-USA.

These educational mini modules outline the relationship between virologic efficacy and adherence to ART, identify the factors that can affect adherence to ART regimens, and describe the strategies to simplify ART and improve or facilitate ART adherence.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:

Drs. Smith and Pellock will provide an expert analysis of the identification of Lennox-Gastaut syndrome in adults, optimal treatment options, and transition of care. The transition of pediatric patients to adults remains a challenge for providers and requires a global multidisciplinary approach.

Activity Summary:
Advances in cancer research unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Mini Modules will review data on castration resistant prostate cancer (CRPC) presented at the 2015 ASCO. Clinical trial data gives new insight into the timing and scheduling of currently approved agents for CRPC. In addition, investigational approaches to CRCP will be presented, as well as information relating to biomarkers and other methods of guiding day-to-day clinical decision-making in this tough-to-treat population.

Activity Summary:
Dr. Smith and Dr. DeToledo provide an expert review of refractory epilepsy, including proper diagnosis, imaging, seizure types, and treatment options including AEDs, surgery, VNS, and dietary considerations.